Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

Inclusion Criteria: * Ability to discern and provide written informed consent and voluntarily adhere to all of the protocol requirements * Male or female subjects in their adult years (≥ 18 years of age), inclusive, from the time of providing written subject-investigator agreement. * Confirmed clinical diagnosis of palmoplantar keratoderma. Exclusion Criteria: * Treatment with any of the following medications and therapies during the duration of the study\*: * Topical corticosteroids * Keratolytic agents (eg, 6% salicylic acid, 70% propylene glycol, 30% water) * Topical retinoids * Topical vitamin D ointment (calcipotriol) * Oral retinoids (acitretin) * If on any of these then a washout period of at least 2 weeks will be enforced before the study begins. This washout period is meant to ensure that any effects or residues from previous treatments are minimized before starting the study. * Prior exposure to Tapinarof treatment * Known history or suspicion of hypersensitivity reactions, or contraindications to any or all components of the drug or drugs of similar properties. * Currently participating in another clinical study for the same purpose. * Potential or confirmed pregnancy: Individuals who are currently pregnant or have confirmed pregnancy at the time of screening will be excluded from participation in the study. This criterion aims to ensure the safety of participants and adhere to ethical considerations regarding the potential risks associated with …